Business Context and Reporting Period
This Form 8-K Current Report was filed by Nurix Therapeutics, Inc. on September 6, 2023. The filing discloses the entry into a Material Definitive Agreement with Seagen Inc. to develop Degrader-Antibody Conjugates (DACs) for cancer treatment using Nurix's proprietary DELigase platform.
Key Financial Metrics
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) as it is a current report regarding a specific event. However, it discloses the following transaction-specific financial terms:
- Upfront Payment: $60 million to be received from Seagen.
- Contingent Milestone Payments: Up to approximately $3.4 billion based on research, development, regulatory, and commercial milestones.
- Royalties: Eligible for mid-single to low double-digit tiered royalties on future sales.
- Profit Sharing: Nurix retains an option for U.S. profit sharing and co-promotion on two products.
Material Changes
The primary material change is the execution of the Collaboration and License Agreement with Seagen Inc. This agreement establishes a strategic partnership where Nurix will develop targeted protein degraders, and Seagen will conjugate them to antibodies to create DACs. This represents a significant expansion of Nurix's commercial pipeline and potential revenue streams compared to prior periods.
Guidance, Outlook, and Risks
Outlook: The collaboration aims to advance multiple DAC drug candidates through preclinical and clinical development toward commercialization. The agreement term is product and country-specific, expiring on the later of patent expiration, regulatory exclusivity expiration, or ten years after the first commercial sale.
Risks and Contingencies: The filing includes forward-looking statements subject to significant risks, including:
- Ability of parties to perform obligations under the agreement.
- Success of preclinical and clinical development and commercialization.
- Potential emergence of adverse events or side effects.
- Nurix's ability to fund development activities.
- Timing and receipt of milestone payments and royalties.
Investor Verification Checklist
- Verify the receipt of the $60 million upfront payment in upcoming cash flow statements.
- Review the full text of the Collaboration Agreement filed as an exhibit to the Form 10-Q for the quarter ending August 31, 2023.
- Monitor the specific milestones required to trigger the $3.4 billion in contingent payments.
- Assess the progress of the first DAC drug candidates entering preclinical development.
- Confirm the exercise of the option for U.S. profit sharing and co-promotion on the two designated products.